Patents by Inventor UTE SCHAEPER

UTE SCHAEPER has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Nucleic acids for inhibiting expression of TMPRSS6 and iron chelators
    Patent number: 12076335
    Abstract: The present invention relates to products and compositions and their uses. In particular the invention relates to nucleic acid products that interfere with the TMPRSS6 gene expression or inhibits its expression in combination with one or more iron chelators and possibly other active agents, as well as therapeutic uses such as for the treatment of hemochromatosis, porphyria and blood disorders such as beta-thalassemia, sickle cell disease and transfusional iron overload or myelodysplastic syndrome, and infections and non-relapse related mortality associated with bone marrow transplantation.
    Type: Grant
    Filed: July 26, 2019
    Date of Patent: September 3, 2024
    Assignee: SILENCE THERAPEUTICS GMBH
    Inventor: Ute Schaeper
  • SIRNA TARGETING TMPRSS6 FOR THE TREATMENT OF MYELOPROLIFERATIVE DISORDERS
    Publication number: 20240240187
    Abstract: The invention relates to a Matriptase-2 (MT2) and/or TMPRSS6 inhibitor for the prevention, decrease of the risk of suffering from or treatment of a myeloproliferative disorder.
    Type: Application
    Filed: April 26, 2022
    Publication date: July 18, 2024
    Inventors: Cavan Bennett, Sant-Rayn Pasricha, Ashley Ng, Sibylle Dames, Ute Schaeper
  • NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF CNNM4 IN A CELL
    Publication number: 20240229041
    Abstract: The invention relates to nucleic acid products that interfere with or inhibit CNNM4 (Cyclin M4) gene expression. It further relates to therapeutic uses of CNNM4 inhibition for the treatment of diseases, such as liver diseases including non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), liver steatosis, liver fibrosis, liver cirrhosis, liver cancer and other diseases associated with magnesium dysregulation.
    Type: Application
    Filed: May 26, 2021
    Publication date: July 11, 2024
    Inventors: Ute SCHAEPER, Sibylle DAMES, Steffen SCHUBERT, Alfonso MARTÍNEZ DE LA CRUZ, Jorge SIMÓN ESPINOSA, Irene GONZALEZ RECIO, María MARTÍNEZ CHANTAR
  • Nucleic acids for inhibiting expression of PROS1 in a cell
    Patent number: 11820971
    Abstract: The invention relates to nucleic acid products that interfere with or inhibit PROS1 gene expression. It further relates to therapeutic uses of PROS1 inhibition for the treatment of bleeding disorders.
    Type: Grant
    Filed: July 25, 2022
    Date of Patent: November 21, 2023
    Assignees: UNIVERSITÄT BERN, SILENCE THERAPEUTICS GMBH
    Inventors: Ute Schaeper, Sibylle Dames, Eliot Morrison, Raja Prince Eladnani, Anne Angelillo-Scherrer
  • NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF CNNM4 IN A CELL
    Publication number: 20230265438
    Abstract: The invention relates to nucleic acid products that interfere with or inhibit CNNM4 (Cyclin M4) gene expression. It further relates to therapeutic uses of CNNM4 inhibition for the treatment of diseases, such as liver diseases including non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), liver steatosis, liver fibrosis, liver cirrhosis, liver cancer and other diseases associated with magnesium dysregulation.
    Type: Application
    Filed: May 26, 2021
    Publication date: August 24, 2023
    Inventors: Ute SCHAEPER, Sibylle DAMES, Steffen SCHUBERT, Alfonso MARTÍNEZ DE LA CRUZ, Jorge SIMÓN ESPINOSA, Irene GONZALEZ RECIO, María Luz MARTÍNEZ CHANTAR
  • NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF PROS1 IN A CELL
    Publication number: 20230019513
    Abstract: The invention relates to nucleic acid products that interfere with or inhibit PROS1 gene expression. It further relates to therapeutic uses of PROS1 inhibition for the treatment of bleeding disorders.
    Type: Application
    Filed: July 25, 2022
    Publication date: January 19, 2023
    Applicants: UNIVERSITÄT BERN, SILENCE THERAPEUTICS GMBH
    Inventors: Ute SCHAEPER, Sibylle DAMES, Eliot MORRISON, Raja PRINCE ELADNANI, Anne ANGELILLO-SCHERRER
  • NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF TMPRSS6 AND IRON CHELATORS
    Publication number: 20220331351
    Abstract: The present invention relates to products and compositions and their uses. In particular the invention relates to nucleic acid products that interfere with the TMPRSS6 gene expression or inhibits its expression in combination with one or more iron chelators and possibly other active agents, as well as therapeutic uses such as for the treatment of hemochromatosis, porphyria and blood disorders such as beta-thalassemia, sickle cell disease and transfusional iron overload or myelodysplastic syndrome, and infections and non-relapse related mortality associated with bone marrow transplantation.
    Type: Application
    Filed: July 26, 2019
    Publication date: October 20, 2022
    Inventor: Ute Schaeper
  • NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF PROS1 IN A CELL
    Publication number: 20220243202
    Abstract: The invention relates to nucleic acid products that interfere with PROS1 gene expression or inhibit its expression. The nucleic acids are particularly for use in the treatment, prevention or reduction of risk of suffering from a bleeding disorder.
    Type: Application
    Filed: May 6, 2020
    Publication date: August 4, 2022
    Applicants: UNIVERSITÄT BERN, SILENCE THERAPEUTICS GMBH
    Inventors: Sibylle DAMES, Ute SCHAEPER, Raja PRINCE ELADNANI, Anne ANGELILLO-SCHERRER
  • NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF PROS1 IN A CELL
    Publication number: 20220135974
    Abstract: The invention relates to nucleic acid products that interfere with or inhibit PROS1 gene expression. It further relates to therapeutic uses of PROS1 inhibition for the treatment of bleeding disorders.
    Type: Application
    Filed: November 11, 2021
    Publication date: May 5, 2022
    Applicants: UNIVERSITÄT BERN, SILENCE THERAPEUTICS GMBH
    Inventors: Ute SCHAEPER, Sibylle DAMES, Eliot MORRISON, Raja PRINCE ELADNANI, Anne ANGELILLO-SCHERRER
  • PRODUCTS AND COMPOSITIONS
    Publication number: 20220025377
    Abstract: The present invention relates to products and compositions and their uses. In particular the invention relates to nucleic acid products that interfere with the TMPRSS6 gene expression or inhibits its expression and therapeutic uses such as for the treatment of hemochromatosis, porphyria and blood disorders such as ?-thalassemias, sickle cell disease and transfusional iron overload or myelodysplastic syndrome.
    Type: Application
    Filed: October 5, 2021
    Publication date: January 27, 2022
    Inventors: Sibylle DAMES, Ute Schaeper, Judith Hauptmann, Christian Frauendorf, Lucas Bethge, Adrien Weingärtner
  • Products and compositions
    Patent number: 11174483
    Abstract: The present invention relates to products and compositions and their uses. In particular the invention relates to nucleic acid products that interfere with the TMPRSS6 gene expression or inhibits its expression and therapeutic uses such as for the treatment of hemochromatosis, porphyria and blood disorders such as ?-thalassemias, sickle cell disease and transfusional iron overload or myelodysplastic syndrome.
    Type: Grant
    Filed: April 5, 2018
    Date of Patent: November 16, 2021
    Assignee: Silence Therapeutics GmbH
    Inventors: Sibylle Dames, Ute Schaeper, Judith Hauptmann, Christian Frauendorf, Lucas Bethge, Adrien Weingärtner
  • PRODUCTS AND COMPOSITIONS
    Publication number: 20200208158
    Abstract: The present invention relates to products and compositions and their uses. In particular the invention relates to nucleic acid products that interfere with the TMPRSS6 gene expression or inhibits its expression and therapeutic uses such as for the treatment of hemochromatosis, porphyria and blood disorders such as ?-thalassemias, sickle cell disease and transfusional iron overload or myelodysplastic syndrome.
    Type: Application
    Filed: April 5, 2018
    Publication date: July 2, 2020
    Applicant: Silence Therapeutics GmbH
    Inventors: Sibylle DAMES, Ute SCHAEPER, Judith HAUPTMANN, Christian FRAUENDORF, Lucas BETHGE, Adrien WEINGÄRTNER
  • MEANS FOR LUNG SPECIFIC DELIVERY
    Publication number: 20190038557
    Abstract: The present invention is related to composition comprising a lipid composition, wherein the lipid composition consists of a cationic lipid of formula (I) wherein n is any one of 1, 2, 3, and 4, wherein m is any one of 1, 2 and 3, Y? is an anion, wherein each of R1 and R2 is individually and independently selected from the group consisting of linear C12-C18 alkyl and linear C12-C18 alkenyl; a sterol compound, wherein the sterol compound is selected from the group consisting of cholesterol and stigmasterol; and a PEGylated lipid, wherein the PEGylated lipid comprises a PEG moiety and wherein the PEGylated lipid is selected from the group consisting of a PEGylated phosphoethanolamine of formula (II) wherein each of R3 and R4 is individually and independently linear C13-C17 alkyl, and p is any integer from 15 to 130; a PEGylated ceramide of formula (III) wherein R5 is linear C7-C15 alkyl, and q is any integer from 15 to 130; and a PEGylated diacylglycerol of formula (IV) wherein each of R6 and R7 is individually
    Type: Application
    Filed: February 14, 2018
    Publication date: February 7, 2019
    Inventors: Oliver KEIL, Jörg KAUFMANN, Volker FEHRING, Ute SCHAEPER
  • MEANS FOR LUNG SPECIFIC DELIVERY
    Publication number: 20160303047
    Abstract: The present invention is related to composition comprising a lipid composition, wherein the lipid composition consists of a cationic lipid of formula (I) wherein n is any one of 1, 2, 3, and 4, wherein m is any one of 1, 2 and 3, Y? is an anion, wherein each of R1 and R2 is individually and independently selected from the group consisting of linear C12-C18 alkyl and linear C12-C18 alkenyl; a sterol compound, wherein the sterol compound is selected from the group consisting of cholesterol and stigmasterol; and a PEGylated lipid, wherein the PEGylated lipid comprises a PEG moiety and wherein the PEGylated lipid is selected from the group consisting of a PEGylated phosphoethanolamine of formula (II) wherein each of R3 and R4 is individually and independently linear C13-C17 alkyl, and p is any integer from 15 to 130; a PEGylated ceramide of formula (III) wherein R5 is linear C7-C15 alkyl, and q is any integer from 15 to 130; and a PEGylated diacylglycerol of formula (IV) wherein each of R6 and R7 is individually
    Type: Application
    Filed: December 5, 2014
    Publication date: October 20, 2016
    Inventors: OLIVER KEIL, JÖRG KAUFMANN, VOLKER FEHRING, UTE SCHAEPER